Canaccord Genuity analyst Edward Nash has maintained their bullish stance on VTYX stock, giving a Buy rating on November 8. Edward ...

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report), with a price target of $6.00. Emily Bodnar’s rating is based on ...

Ventyx Biosciences (NASDAQ:VTYX) files prospectus the offer and resale from time to time of up to 7,060,100 shares of common stock. SEC Filing More on Ventyx Biosciences Ventyx Biosciences: R ...

Revenue in Q3 2024 decreased by $3.8 million to $61.6 million as compared to $65.4 million in Q3 2023. The year-over-year decrease in revenue can primarily be attributed to a decrease in retail ...

Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors ...

Ventyx stock shows all the characteristics of a highly underappreciated issue with surprisingly valuable assets that can be ...

China Universal Asset Management Co. Ltd. lifted its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) by 64.1% ...

Wells Fargo has recently raised Ventyx Biosciences Inc (VTYX) stock to Overweight rating, as announced on March 12, 2024, according to Finviz. Earlier, on March 12, 2024, Oppenheimer had raised the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of October 21, 2024, Ventyx Biosciences Inc had a $179.5 million market capitalization, putting it in the 29th percentile of companies in the Pharmaceuticals industry. Ventyx Biosciences Inc does ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...